文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

PROMIS量表在慢性皮肤病中的测量性能

Measurement Properties of PROMIS Measures Relevant to Chronic Skin Diseases.
PubMed 文献 · JAMA Dermatol · 2026-01-01

这项队列研究纳入549例美国慢性皮肤病患者,基线及3个月后完成PROMIS简表及其他量表,评估结构效度、内部一致性、建构效度和反应性。焦虑、抑郁、社会满意和社会隔离简表结构效度与内部一致性良好;疼痛和瘙痒强度单条目反应性与Skindex-29症状域相近;焦虑和抑郁反应性低于Skindex-29情绪域。

要点

  • PROMIS焦虑、抑郁、社会满意和社会隔离简表在慢性皮肤病中结构效度与内部一致性良好。
  • 疼痛和瘙痒强度单条目反应性与Skindex-29症状域相似,可用于追踪治疗改善。
  • 焦虑和抑郁简表反应性低于Skindex-29情绪域,评估情绪变化时需注意。

核心结论

  • PROMIS量表可有效评估慢性皮肤病对身体、情绪和社会的影响。
  • 身体和社会影响相关测量能追踪治疗后的改善。

研究设计与样本

  • 队列研究,2025年2月通过在线平台在美国招募549例18岁及以上自报慢性皮肤病的成人。
  • 基线完成PROMIS及其他量表调查,3个月后完成随访调查。
  • 249例(45.1%)有特应性皮炎,246例(44.8%)有痤疮,113例(20.6%)有银屑病。

主要发现

  • 焦虑、抑郁、社会满意和社会隔离简表结构效度充分(CFI和/或TLI大于0.95;SRMR小于0.08)。
  • 上述简表内部一致性良好(Cronbach α大于0.90)。
  • 所有测量在已知组和聚合效度检验中显示充分建构效度(相似构念间Pearson相关系数≥0.30)。
  • 疼痛(SRM 0.41)和瘙痒强度(SRM范围0.32-0.44)的反应性与Skindex-29症状域(SRM 0.47)相似。
  • 社会满意(SRM -0.20)和社会隔离(SRM 0.27)的反应性与Skindex-29功能域(SRM 0.25)相似;焦虑(SRM 0.11)和抑郁(SRM 0.16)反应性低于Skindex-29情绪域(SRM 0.43)。

关键数值与推荐

  • 结构效度:CFI和/或TLI大于0.95,SRMR小于0.08。
  • 内部一致性:Cronbach α大于0.90。
  • 建构效度:相似构念间Pearson相关系数≥0.30。

临床怎么用

  • 可将PROMIS简表整合到皮肤科临床,评估慢性皮肤病患者的身体、情绪和社会影响。
  • 疼痛和瘙痒强度单条目及社会满意/隔离简表可用于追踪治疗后的改善。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patient-Reported Outcomes Measurement Information System (PROMIS) is a generalized set of patient-reported outcome measures (PROMs) that can be readily integrated into the dermatologic clinic setting, but the measurement properties of these PROMs among patients with a range of chronic skin diseases have yet to be established. OBJECTIVE: To evaluate the structural validity, internal consistency, construct validity, and responsiveness of PROMIS short-form measures for anxiety, depression, social satisfaction, and social isolation as well as the construct validity and responsiveness of single-item pain and itch intensity measures. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, adults 18 years and older with a self-reported chronic skin disease (eg, atopic dermatitis, acne, psoriasis) were recruited in February 2025 from across the US via an online survey platform. Enrolled participants completed a baseline survey of PROMIS and several other relevant measures and then a follow-up survey 3 months later. MAIN OUTCOMES AND MEASURES: Measures collected include the PROMIS measures, Dermatology Life Quality Index, Skindex-29, a baseline patient global assessment, and a change in skin disease anchor question at follow-up. Structural validity, internal consistency, construct validity, and responsiveness were evaluated for the short-form measures. Construct validity and responsiveness were assessed for the single-item measures. RESULTS: Of 549 included participants with chronic skin diseases, 287 (52.3%) were female, 262 (47.7%) were male, and the median (IQR) age was 36 (30-45) years. A total of 249 patients (45.1%) had atopic dermatitis, 246 (44.8%) had acne, and 113 (20.6%) had psoriasis. The anxiety, depression, social satisfaction, and social isolation short-form measures demonstrated adequate structural validity (ie, all with comparative fit index and/or Tucker-Lewis index values greater than 0.95; standardized root mean residual values less than 0.08) and internal consistency (Cronbach α values greater than 0.90). All measures showed sufficient construct validity on known-groups and convergent validity testing (eg, magnitude of Pearson correlations between measures evaluating similar underlying constructs with values of 0.30 or greater). When comparing responsiveness based on standardized response means (SRMs), the pain (SRM, 0.41) and itch intensity (SRM range, 0.32-0.44) measures showed similar responsiveness as the Skindex-29 symptoms domain (SRM, 0.47), and the social satisfaction (SRM, -0.20) and isolation (SRM, 0.27) measures showed similar responsiveness to the Skindex-29 functioning domain (SRM, 0.25). Responsiveness of the anxiety (SRM, 0.11) and depression (SRM, 0.16) measures were lower than the Skindex-29 emotions domain (SRM, 0.43). CONCLUSIONS AND RELEVANCE: In this study, PROMIS measures were valid for assessing the physical, emotional, and social effects of chronic skin diseases, and measures for physical and social impact tracked improvements with treatment.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Nock MR, Ershadi S, Sánchez-Feliciano A, et al. Measurement Properties of PROMIS Measures Relevant to Chronic Skin Diseases. JAMA Dermatol. 2026. PMID: 41432938. doi:10.1001/jamadermatol.2025.5163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。